| Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors (NCT06504368) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2024-05-29 |
| A Study of DCR-STAT3 in Adults With Solid Tumors (NCT06098651) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2023-08-14 |
| Phase 1b Study of DCR-AUD in Healthy Volunteers (NCT05845398) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2023-01-29 |
| Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (NCT05001269) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2022-02-22 |
| An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD) (NCT05146882) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-12-01 |
| Study of DCR-AUD in Healthy Volunteers (NCT05021640) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-09-21 |
| Natural History of Patients With PH3 and a History of Stone Events (NCT04542590) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-09-09 |
| Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD (NCT04580420) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-04-15 |
| A Study of Belcesiran in Patients With AATLD (NCT04764448) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-02-12 |
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (NCT04555486) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2020-09-14 |
| Study of DCR-A1AT in Healthy Adult Volunteers (NCT04174118) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2019-10-24 |
| Long Term Extension Study in Patients With Primary Hyperoxaluria (NCT04042402) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2019-07-09 |
| Study of Safety and Tolerability of DCR HBVS (NCT03772249) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2018-12-28 |
| Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria (NCT03392896) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2017-12-06 |
| A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) (NCT02795325) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2016-05-13 |
| Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma (NCT02314052) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2015-01-27 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (NCT02110563) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2014-04-01 |
| Treatment of Primary Hyperoxaluria Type 1 With Nedosiran (NCT05993416) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | |